DanDi Bioscience

https://www.hankyung.com/it/article/202306025154i 

This post has been translated from the original article dated 06/02/2023.

HLB Science Agrees With NordCure To Joint Microbiome Research

Pipeline Extension Start

HLB Science announced on the 2nd that it has signed an agreement with NordCure for microbiome-based joint research.

Nordcure has microbiome-based metabolic and immune disease treatment technology. It was founded in 2021 by Professor Park Jong-hwan of Chonnam National University's College of Veterinary Medicine. It is developing treatments for anticancer, infectious diseases, metabolic and immune diseases based on microbiome-based pharmaceutical materials.

According to the agreement, HLB Science will conduct joint research in the field of NordCure and the microbiome. Through this, we plan to review the scalability of new drug candidates (pipeline).

HLB Science is currently developing DD-S052P, an antibiotic for the treatment of sepsis and super bacteria. Phase 1 clinical trials are underway in France. It was xxselected as the operator of the "2023 First Health and Medical Technology R&D Project" organized by the Ministry of Health and Welfare on the 17th of last month. It will receive 2.75 billion won in research funds for three years.

Unlike existing treatments, microbiome treatments are in the spotlight because they have fewer side effects and can suggest new treatments, said Yoon Jong-sun, CEO of HLB Science. "We will increase corporate value in cooperation with NordCure, which has excellent technology and research capabilities."